A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. [electronic resource]
Producer: 20160815Description: 457-65 p. digitalISSN:- 1938-0690
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Cycle Proteins -- antagonists & inhibitors
- Drug Dosage Calculations
- Drug Interactions
- Drug Resistance, Neoplasm
- Drug Therapy, Combination
- Fatigue -- etiology
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Nausea -- etiology
- Pemetrexed -- administration & dosage
- Platinum Compounds -- therapeutic use
- Protein Serine-Threonine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins -- antagonists & inhibitors
- Pteridines -- administration & dosage
- Survival Analysis
- Polo-Like Kinase 1
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.